The chemical name **1-[4-(4-aminophenyl)-1-piperazinyl]ethanone** refers to a compound that is commonly known as **N-(4-aminophenyl)piperazine-1-ethanone** or **PAE**.
**Structure and Properties:**
* **PAE** is an organic compound that contains a piperazine ring, an amide group, and an aniline moiety.
* It is a white to off-white solid that is soluble in organic solvents.
**Importance in Research:**
**1. Potential Therapeutic Applications:**
* **Antidepressant activity:** PAE has shown promising antidepressant activity in preclinical studies. It is believed to act as a serotonin and dopamine reuptake inhibitor, similar to other antidepressant medications.
* **Anti-inflammatory activity:** PAE has also demonstrated anti-inflammatory properties in animal models of inflammation. Its mechanism of action may involve modulation of inflammatory signaling pathways.
* **Analgesic activity:** Some studies suggest that PAE may possess analgesic properties, potentially by interfering with pain signaling pathways.
**2. Chemical and Biological Probe:**
* **Synthetic building block:** PAE is a versatile building block for the synthesis of other bioactive compounds. Its functional groups can be modified to create novel molecules with different pharmacological properties.
* **Tool for studying biological targets:** PAE can be used as a tool to study the binding properties and pharmacological effects of specific receptors or enzymes.
**3. Research into Piperazine Derivatives:**
* **Structure-activity relationship studies:** PAE serves as a lead compound for investigating the structure-activity relationship of piperazine derivatives. By modifying its chemical structure, researchers can explore the effects of different functional groups on pharmacological activity.
* **Development of new drugs:** PAE provides a starting point for the development of new drugs targeting various disease conditions.
**Important Note:**
While PAE shows potential therapeutic benefits, it is still in the early stages of research. Extensive preclinical and clinical studies are necessary to determine its safety and efficacy before it can be considered for human use.
**Disclaimer:** I am an AI chatbot and cannot provide medical advice. If you have any questions or concerns about specific medical conditions or treatments, please consult a qualified healthcare professional.
ID Source | ID |
---|---|
PubMed CID | 736269 |
CHEMBL ID | 1700038 |
CHEBI ID | 92497 |
SCHEMBL ID | 188503 |
Synonym |
---|
BB 0244747 |
1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethano ne |
NCGC00182616-01 |
OPREA1_693361 |
SDCCGMLS-0064968.P001 |
TIMTEC1_007041 |
1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanone |
4-(4-acetyl-1-piperazinyl)aniline |
92394-00-8 |
STK029286 |
1-[4-(4-aminophenyl)piperazin-1-yl]ethanone |
HMS1554A01 |
AKOS000104069 |
1-(4-(4-aminophenyl)piperazin-1-yl)ethanone |
BRD-K28362289-001-01-7 |
smr001317784 |
MLS002264484 |
1-[4-(4-aminophenyl)piperazin-1-yl]ethan-1-one |
HMS2213K16 |
1-(4-(4-aminophenyl)piperazin-1-yl)ethanone;1-acetyl-4-(4-aminophenyl)piperazine |
1-acetyl-4-(4-aminophenyl)piperazine |
FT-0604244 |
PS-5341 |
HMS3356E21 |
SCHEMBL188503 |
[4-(4-acetylpiperazin-1-yl)phenyl]amine |
1-(4-(4-aminophenyl)piperazin-1-yl)ethan-1-one |
4-(4-acetylpiperazin-1-yl) aniline |
4-(4-acetylpiperazino)-aniline |
AFVUJJNEILZYJQ-UHFFFAOYSA-N |
1-acetyl-4-(4-amino-phenyl)piperazine |
1-actyl-4-(4-aminophenyl)piperazine |
1-[4-(4-amino-phenyl)-piperazin-1-yl]ethanone |
4-acetyl-1-(4-aminophenyl)piperazine |
4-(4-acetylpiperazin-1-yl)aniline |
[4-(4-acetyl-1-piperazinyl)phenyl]amine |
mfcd01365904 |
SY019137 |
CHEMBL1700038 |
AC-26278 |
1-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanone, aldrichcpr |
DTXSID90352984 |
CHEBI:92497 |
1-[4-(4-aminophenyl)-1-piperazinyl]ethanone |
Q27164229 |
1-[4-(4-aminophenyl)piperazino]ethanone |
AMY36335 |
EN300-343896 |
Class | Description |
---|---|
piperazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 39.8107 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 39.8107 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 10.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
plasminogen precursor | Mus musculus (house mouse) | Potency | 10.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 10.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 16.2300 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Caspase 6, apoptosis-related cysteine peptidase | Homo sapiens (human) | AC50 | 11.1500 | 0.0636 | 11.2358 | 44.9700 | AID720632 |
FAD-linked sulfhydryl oxidase ALR | Homo sapiens (human) | AC50 | 1.0570 | 0.0050 | 3.2126 | 22.7870 | AID493248 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |